Reported about 14 hours ago
This article discusses two healthcare stocks, Novo Nordisk and DexCom, that present attractive buying opportunities after recent market underperformance. Novo Nordisk, despite recent setbacks, has promising growth prospects in weight management and an expanding pipeline of treatments beyond diabetes. DexCom, a leader in diabetes monitoring technology, faces short-term challenges but has significant long-term potential due to its low market penetration and growing insurance coverage. Both companies are positioned for strong recovery over the next decade.
Source: YAHOO